Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
NCT07457177
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
NK T-Cell Lymphoma
Interventions
DRUG:
Golidocitinib + Pegaspargase + Anti-PD-1 mAb
Sponsor
LIANG WANG